modelC10AX09

Diagram of C10AX09

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Ezetimibe
ATC code:C10AX09
route:oral
compartments:2
dosage:10mg
volume of distribution:49.5L
clearance:25L/h
other parameters in model implementation

Ezetimibe is a lipid-lowering agent that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. It is used as adjunctive therapy to diet for the reduction of elevated total cholesterol, LDL cholesterol, and apolipoprotein B. Ezetimibe is approved for use in the treatment of hypercholesterolemia and is frequently used in combination with statins.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose administration.

References

  1. Soulele, K, & Karalis, V (2019). On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Xenobiotica; the fate of foreign compounds in biological systems 49(4) 446–456. DOI:10.1080/00498254.2018.1463117 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29629619

  2. Simard, C, & Turgeon, J (2003). The pharmacokinetics of ezetimibe. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 10 Suppl A 13A–20A. PUBMED:https://pubmed.ncbi.nlm.nih.gov/14571304

  3. Wada, S, et al., & Nakagami, H (2023). Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions. Clinical pharmacology in drug development 12(7) 731–738. DOI:10.1002/cpdd.1245 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37021410

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)